Johnson & Johnson (JNJ)
NYSE: JNJ · IEX Real-Time Price · USD
146.03
-0.41 (-0.28%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $81.80B in the twelve months ending March 31, 2024, with 5.60% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $21.38B with 2.34% year-over-year growth. In the year 2023, Johnson & Johnson had annual revenue of $85.16B with 6.46% growth.
Revenue (ttm)
$81.80B
Revenue Growth
+5.60%
P/S Ratio
4.30
Revenue / Employee
$620,136
Employees
131,900
Market Cap
351.45B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
Dec 29, 2019 | 82.06B | 478.00M | 0.59% |
Dec 30, 2018 | 81.58B | 5.13B | 6.71% |
Dec 31, 2017 | 76.45B | 4.56B | 6.34% |
Jan 1, 2017 | 71.89B | 1.82B | 2.59% |
Jan 3, 2016 | 70.07B | -4.26B | -5.73% |
Dec 28, 2014 | 74.33B | 3.02B | 4.23% |
Dec 29, 2013 | 71.31B | 4.09B | 6.08% |
Dec 30, 2012 | 67.22B | 2.19B | 3.37% |
Jan 1, 2012 | 65.03B | 3.44B | 5.59% |
Jan 2, 2011 | 61.59B | -310.00M | -0.50% |
Jan 3, 2010 | 61.90B | -1.85B | -2.90% |
Dec 28, 2008 | 63.75B | 2.65B | 4.34% |
Dec 30, 2007 | 61.10B | 7.77B | 14.57% |
Dec 31, 2006 | 53.32B | 2.81B | 5.56% |
Jan 1, 2006 | 50.51B | 3.17B | 6.69% |
Jan 2, 2005 | 47.35B | 5.49B | 13.10% |
Dec 28, 2003 | 41.86B | 5.56B | 15.33% |
Dec 29, 2002 | 36.30B | 3.98B | 12.32% |
Dec 30, 2001 | 32.32B | 3.15B | 10.78% |
Dec 31, 2000 | 29.17B | 1.17B | 4.16% |
Dec 30, 1999 | 28.01B | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 379.49B |
Merck & Co. | 61.40B |
AbbVie | 54.40B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.49B |
Abbott Laboratories | 40.33B |
Eli Lilly | 35.93B |
JNJ News
- 15 hours ago - CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study - PRNewsWire
- 4 days ago - Cancer victims lose bid to block proposed J&J talc bankruptcy - Reuters
- 4 days ago - Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients - PRNewsWire
- 4 days ago - Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga
- 5 days ago - Lawyers for Johnson & Johnson's Ovarian Cancer Victims React to SCOTUS Decision in Purdue - Business Wire
- 11 days ago - Johnson & Johnson Completes Acquisition of Proteologix, Inc. - Business Wire
- 12 days ago - Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease - PRNewsWire
- 12 days ago - More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme - Business Wire